In this study, ERK and AKT kinase-targeted drugs and their combinations with conventional chemotherapeutics were tested on lung adenocarcinoma cell line A549 and ex vivo lung cancer patient-derived heterogeneous cell line sets as a model system. The gene discussed is AKT1; the disease is lung carcinoma.